Current research studies on the treatment of recurrent current ovarian cancer focus on new chemotherapeutic agents and biomolecular targeting agents. The role of surgery for recurrent ovarian cancer remains controversial. Abundant retrospective series report on the prolongation of survival with secondary cytoreductive surgery in recurrent ovarian cancer has been well-known. In recent reports, complete optimal secondary cytoreductive surgery in the management of the recurrent ovarian cancer presenting as isolated node metastases was feasible, and also showed a favorable result.